7	16	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 7), 'text':'Cancer is a disease of genome alterations :'}, {'start':(0, 8), 'end':(0, 33), 'text':'DNA sequence changes , copy number aberrations , chromosomal rearrangements , and modification in DNA methylation together drive the development and progression of human malignancies .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(1, 0), 'end':(1, 15), 'text':'With the complete sequencing of the human genome and continuing improvement of high-throughput genomic technologies ,'}, {'start':(1, 16), 'end':(1, 28), 'text':'it is now feasible to contemplate comprehensive surveys of human cancer genomes .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(2, 0), 'end':(2, 9), 'text':'The Cancer Genome Atlas ( TCGA ) aims to catalogue'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 10), 'end':(2, 13), 'text':'and discover major cancer'}, {'start':(2, 14), 'end':(2, 27), 'text':'causing genome alterations in large cohorts of human tumors through integrated multi-dimensional analyses .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 2), 'text':'The first cancer'}, {'start':(3, 3), 'end':(3, 20), 'text':'studied by TCGA is glioblastoma ( GBM ) , the most common primary brain tumor in adults .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 2), 'text':'Primary GBM ,'}, {'start':(4, 3), 'end':(4, 14), 'text':'which comprises more than 90 % of biopsied or resected cases ,'}]}, {'start':(4, 15), 'end':(4, 25), 'text':'arises de novo without antecedent history of low grade disease ,'}]}, {'start':(4, 26), 'end':(4, 35), 'text':'whereas secondary GBM progresses from previously diagnosed low-grade gliomas .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 21), 'text':'Patients with newly diagnosed GBM have a median survival of approximately one year with generally poor responses to all therapeutic modalities .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 13), 'text':'Two decades of molecular studies have identified important genetic events in human GBMs ,'}, {'start':(6, 14), 'end':(6, 36), 'text':'including ( i ) dysregulation of growth factor signaling via amplification and mutational activation of receptor tyrosine kinase ( RTK ) genes ;'}]}, {'start':(6, 37), 'end':(6, 50), 'text':'( ii ) activation of the phosphatidyl inositol 3-kinase ( PI3K ) pathway ;'}]}, {'start':(6, 51), 'end':(6, 64), 'text':'and ( iii ) inactivation of the p53 and retinoblastoma tumor suppressor pathways .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'background', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 19), 'text':'Recent genome-wide profiling studies have also shown remarkable genomic heterogeneity among GBM and the existence of molecular subclasses within GBM'}, {'start':(7, 20), 'end':(7, 22), 'text':'that may ,'}]}, {'start':(7, 23), 'end':(7, 26), 'text':'when fully defined ,'}]}, {'start':(7, 27), 'end':(7, 31), 'text':'allow stratification of treatment -.'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 11), 'text':'Albeit fragmentary , such baseline knowledge of GBM genetics sets the stage'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(8, 12), 'end':(8, 13), 'text':'to explore'}, {'start':(8, 14), 'end':(8, 29), 'text':'whether novel insights can be gained from a more systematic examination of the GBM genome .'}]}]}]}]}]}
16	113	{'label':'topic-change', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'Results'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 12), 'text':'As a public resource , all TCGA data are deposited at the Data'}, {'start':(1, 13), 'end':(1, 14), 'text':'Coordinating Center'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 15), 'end':(1, 20), 'text':'( DCC ) for public access'}, {'start':(1, 21), 'end':(1, 24), 'text':'( http://cancergenome.nih.gov/ ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 18), 'text':'TCGA data are classified by data type ( e.g. clinical , mutations , gene expression ) and data level'}, {'start':(2, 19), 'end':(2, 31), 'text':'to allow structured access to this resource with appropriate patient privacy protection .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(3, 0), 'end':(3, 10), 'text':'An overview of the data organization is provided in Methods ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 11), 'end':(3, 21), 'text':'and a detailed description is available in the TCGA Data Primer'}, {'start':(3, 22), 'end':(3, 25), 'text':'( http://tcga-data.nci.nih.gov/docs/TCGA_Data_Primer.pdf ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 1), 'text':'Biospecimen collection'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 8), 'text':'Retrospective biospecimen repositories were screened for newly diagnosed GBM'}, {'start':(5, 9), 'end':(5, 19), 'text':'based on surgical pathology reports and clinical records ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 2), 'text':'Samples were further'}, {'start':(6, 3), 'end':(6, 21), 'text':'selected for having matched peripheral blood as well as associated demographic , clinical and pathological data ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 9), 'text':'Corresponding frozen tissues were reviewed at the Biospecimen Core Resource'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(7, 10), 'end':(7, 12), 'text':'( BCR )'}, {'start':(7, 13), 'end':(7, 31), 'text':'to ensure a minimum of 80 % tumor nuclei and a maximum of 50 % necrosis ( ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 2), 'text':'DNA and RNA'}, {'start':(8, 3), 'end':(8, 27), 'text':'extracted from qualified biospecimens were subjected to additional quality control measurements ( Methods ) prior to distribution to TCGA centers for analyses ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 1), 'text':'After exclusion'}, {'start':(9, 2), 'end':(9, 24), 'text':'based on insufficient tumor content ( n = 234 ) and suboptimal nucleic acid quality or quantity ( n = 147 ) ,'}]}, {'start':(9, 25), 'end':(9, 47), 'text':'206 of the 587 biospecimens screened ( 35 % ) were qualified for copy number , expression , and DNA methylation analyses .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(10, 0), 'end':(10, 10), 'text':'Of these , 143 cases had matched normal peripheral blood DNAs'}, {'start':(10, 11), 'end':(10, 17), 'text':'and were therefore appropriate for re-sequencing .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 7), 'text':'This cohort also included 21 post-treatment GBM cases'}, {'start':(11, 8), 'end':(11, 14), 'text':'used for exploratory comparisons ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(12, 0), 'end':(12, 22), 'text':'While it is possible that a small number of progressive secondary GBMs were among the remaining 185 cases of newly diagnosed glioblastomas ,'}, {'start':(12, 23), 'end':(12, 29), 'text':'this cohort represents predominantly primary GBM .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(13, 0), 'end':(13, 1), 'text':'Indeed ,'}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(13, 2), 'end':(13, 7), 'text':'when compared with published cohorts ,'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 8), 'end':(13, 21), 'text':'overall survival of the newly diagnosed glioblastoma cases in TCGA is similar to that'}, {'start':(13, 22), 'end':(13, 27), 'text':'reported in the literature ( ,'}]}, {'start':(13, 28), 'end':(13, 33), 'text':'p = 0.2 ) - .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 3), 'text':'Genomic and transcriptional aberrations'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 12), 'text':'Genomic copy number alterations ( CNAs ) were measured on three microarray platforms'}, {'start':(15, 13), 'end':(15, 15), 'text':'( Methods )'}]}, {'start':(15, 16), 'end':(15, 24), 'text':'and analyzed with multiple analytical algorithms- ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(16, 0), 'end':(16, 6), 'text':'Besides the well-known alterations , , ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 7), 'end':(16, 22), 'text':'we detected significantly recurrent focal alterations not previously reported in GBMs , such as homozygous deletions'}, {'start':(16, 23), 'end':(16, 31), 'text':'involving NF1 and PARK2 and amplifications of AKT3 .'}]}]}, {'start':(17, 0), 'end':(17, 25), 'text':'Search for informative but infrequent CNAs also uncovered rare focal events , such as amplifications of FGFR2 and IRS2 and deletion of PTPRD ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 0), 'end':(18, 30), 'text':'Abundances of protein coding genes and non coding microRNA were also measured by transcript specific and exon specific probes on multiple platforms ( Methods , and manuscript in preparation ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(19, 0), 'end':(19, 7), 'text':'The resulting integrated gene expression data set showed'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 8), 'end':(19, 19), 'text':'that ~ 76 % of genes within recurrent CNAs have expression patterns'}, {'start':(19, 20), 'end':(19, 27), 'text':'that correlate with copy number ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 3), 'text':'In addition , SNP'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 4), 'end':(20, 11), 'text':'based analyses also catalogued copy-neutral loss of heterozygosity'}, {'start':(20, 12), 'end':(20, 15), 'text':'( LOH ) ,'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 16), 'end':(20, 20), 'text':'with the most significant region'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 21), 'end':(20, 23), 'text':'being 17p ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 24), 'end':(20, 26), 'text':'which contains TP53'}, {'start':(20, 27), 'end':(20, 30), 'text':'( Methods ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 6), 'text':'Patterns of somatic nucleotide alterations in GBM'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 0), 'end':(22, 3), 'text':'91 matched tumor-normal pairs'}, {'start':(22, 4), 'end':(22, 11), 'text':'( 72 untreated and 19 treated cases )'}]}, {'start':(22, 12), 'end':(22, 29), 'text':'were selected from the 143 cases for detection of somatic mutations in 601 selected genes ( ) .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 0), 'end':(23, 3), 'text':'The resulting sequences ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 4), 'end':(23, 8), 'text':'totaling 97 million base pairs'}, {'start':(23, 9), 'end':(23, 18), 'text':'( 1.1+ / -0.1 million bases per sample ) ,'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 19), 'end':(23, 20), 'text':'uncovered 453'}, {'start':(23, 21), 'end':(23, 30), 'text':'validated non silent somatic mutations ( ; http://tcga-data.nci.nih.gov/docs/somatic_mutations/tcga_mutations.htm ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 0), 'end':(24, 11), 'text':'The background mutation rates differed drastically between untreated and treated GBMs ,'}, {'start':(24, 12), 'end':(24, 39), 'text':'averaging 1.4 versus 5.8 somatic silent mutations per sample ( 98 among 72 untreated vs 111 among 19 treated , p < 10 -21 ) , respectively .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 0), 'end':(25, 9), 'text':'This difference was predominantly driven by seven hypermutated samples ,'}, {'start':(25, 10), 'end':(25, 23), 'text':'as determined by frequencies of both silent and non silent mutations ( ) .'}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 0), 'end':(26, 8), 'text':'Four of the 7 hypermutated tumors were from patients'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 9), 'end':(26, 16), 'text':'previously treated with temozolomide and 3 from patients'}, {'start':(26, 17), 'end':(26, 26), 'text':'treated with CCNU alone or in combination ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 0), 'end':(27, 16), 'text':'A hypermutator phenotype in GBM has been described in 3 GBM specimens with MSH6 mutations , ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 17), 'end':(27, 26), 'text':'prompting us to perform a systematic analysis of the genes'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 27), 'end':(27, 30), 'text':'involved in mismatch repair'}, {'start':(27, 31), 'end':(27, 34), 'text':'( MMR ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 0), 'end':(28, 5), 'text':'Indeed , 6 of the 7'}, {'start':(28, 6), 'end':(28, 27), 'text':'hypermutated samples harbored mutations in at least one of the mismatch repair genes MLH1 , MSH2 , MSH6 , or PMS2 ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 28), 'end':(28, 39), 'text':'as compared with only one sample among the 84 non hypermutated samples'}, {'start':(28, 40), 'end':(28, 46), 'text':'( p = 7x10 -8 ) ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 47), 'end':(28, 59), 'text':'suggesting a role of decreased DNA repair competency in these highly mutated samples'}, {'start':(28, 60), 'end':(28, 64), 'text':'derived from treated patients .'}]}]}]}, {'label':'manner-means', 'direction':'RightToLeft', 'children':[{'start':(29, 0), 'end':(29, 8), 'text':'By applying a statistical analysis of mutation significance ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(29, 9), 'end':(29, 12), 'text':'we identified eight genes'}, {'start':(29, 13), 'end':(29, 27), 'text':'as significantly mutated ( false discovery rate ( FDR ) < 10 -3 ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 0), 'end':(30, 28), 'text':'Interestingly , 27 TP53 mutations were detected in the 72 untreated GBMs ( 37.5 % ) and 11 mutations in the 19 treated samples ( 58 % ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(31, 0), 'end':(31, 3), 'text':'All of those mutations'}, {'start':(31, 4), 'end':(31, 10), 'text':'clustered in the DNA binding domain ,'}]}, {'start':(31, 11), 'end':(31, 22), 'text':'a well-known hotspot for p53 mutations in human cancers ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 0), 'end':(32, 11), 'text':'Given the predominance of primary GBM among this newly diagnosed collection ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(32, 12), 'end':(32, 15), 'text':'that result unequivocally proves'}, {'start':(32, 16), 'end':(32, 26), 'text':'that p53 mutation is a common event in primary GBM .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(33, 0), 'end':(33, 6), 'text':'NF1 is a human glioblastoma suppressor gene'}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(34, 0), 'end':(34, 16), 'text':'Although somatic mutations in NF1 have been reported in a small series of human GBM tumors ,'}, {'label':'contrast', 'direction':'LeftToRight', 'children':[{'start':(34, 17), 'end':(34, 21), 'text':'their role remains controversial ,'}, {'start':(34, 22), 'end':(34, 31), 'text':'despite strong genetic data in mouse model systems , .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(35, 0), 'end':(35, 17), 'text':'Here , 19 NF1 somatic mutations were identified in 13 samples ( 14 % of 91 ) ,'}, {'start':(35, 18), 'end':(35, 38), 'text':'including six nonsense mutations , four splice site mutations , five missense changes , and four frameshift indels ( ) .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(36, 0), 'end':(36, 3), 'text':'Five of these mutations'}, {'start':(36, 4), 'end':(36, 26), 'text':'-- R1391S ( ) , R1513 * ( ) , e25 -1 and e29 +1 ( ) , and Q1966 * ( )'}]}, {'start':(36, 27), 'end':(36, 37), 'text':'-- have been reported as germline alterations in neurofibromatosis patients ,'}]}, {'start':(36, 38), 'end':(36, 42), 'text':'thus are likely inactivating .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(37, 0), 'end':(37, 19), 'text':'In addition , 30 heterozygous deletions in NF1 were observed among the entire interim sample set of 206 cases ,'}, {'start':(37, 20), 'end':(37, 29), 'text':'6 of which also harbor point mutation ( ) .'}]}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(38, 0), 'end':(38, 6), 'text':'Some samples also exhibited loss of expression'}, {'start':(38, 7), 'end':(38, 14), 'text':'without evidence of genomic alteration ( ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(39, 0), 'end':(39, 31), 'text':'Overall , at least 47 of these 206 patient samples ( 23 % ) harbored somatic NF1 inactivating mutations or deletions , definitively address NF1 \'s relevance to sporadic human GBM .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(40, 0), 'end':(40, 4), 'text':'Prevalence of EGFR family activation'}, {'start':(41, 0), 'end':(41, 7), 'text':'EGFR is frequently activated in primary GBMs .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(42, 0), 'end':(42, 14), 'text':'Variant III deletion of the extracellular domain ( so called " vIII mutant " )'}, {'start':(42, 15), 'end':(42, 22), 'text':'has been the most commonly described event ,'}]}, {'start':(42, 23), 'end':(42, 34), 'text':'in addition to extracellular domain point mutations and cytoplasmic domain deletions .'}]}, {'start':(43, 0), 'end':(43, 0), 'text':'.'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(44, 0), 'end':(44, 22), 'text':'Here , high resolution genomic and exon specific transcriptomic profiling readily detected vIII and C-terminal deletions with correspondingly altered transcripts ( ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(45, 0), 'end':(45, 10), 'text':'Among the 91 GBM cases with somatic mutation data , 22'}, {'start':(45, 11), 'end':(45, 44), 'text':'harbored focal amplification of wild type EGFR with no point mutation , 16 had point mutations in addition to focal amplification , and three had EGFR point mutations but no amplification ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(46, 0), 'end':(46, 10), 'text':'Collectively , EGFR alterations were observed in 41 of the 91'}, {'start':(46, 11), 'end':(46, 13), 'text':'sequenced samples .'}]}]}]}]}]}, {'label':'contrast', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(47, 0), 'end':(47, 11), 'text':'ERBB2 mutation has previously been reported in only one GBM tumor .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(48, 0), 'end':(48, 16), 'text':'In the TCGA cohort , 11 somatic ERBB2 mutations in 7 of 91 samples were validated ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(48, 17), 'end':(48, 24), 'text':'including 3 in the kinase domain and two'}, {'start':(48, 25), 'end':(48, 45), 'text':'involving V777A , a site of recurrent missense and in-frame insertion mutations in lung , gastric , and colon cancers .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(49, 0), 'end':(49, 3), 'text':'The remaining eight mutations'}, {'start':(49, 4), 'end':(49, 13), 'text':'( including seven missense and one splice site mutation )'}]}, {'start':(49, 14), 'end':(49, 32), 'text':'occurred in the extracellular domain of the protein , similar to somatic EGFR substitutions in GBM ( ) .'}]}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(50, 0), 'end':(50, 4), 'text':'Unlike in breast cancers ,'}, {'start':(50, 5), 'end':(50, 14), 'text':'focal amplifications of ERBB2 were not observed in GBMs .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(51, 0), 'end':(51, 8), 'text':'Somatic mutations of the PI3K complex in human glioblastoma'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(52, 0), 'end':(52, 13), 'text':'The PI3 kinase complex is comprised of a catalytically active protein , p110alpha ,'}, {'start':(52, 14), 'end':(52, 17), 'text':'encoded by PIK3CA ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(52, 18), 'end':(52, 24), 'text':'and a regulatory protein , p85alpha ,'}, {'start':(52, 25), 'end':(52, 28), 'text':'encoded by PIK3R1 .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(53, 0), 'end':(53, 13), 'text':'Frequent activating missense mutations of PIK3CA have been reported in multiple tumor types ,'}, {'start':(53, 14), 'end':(53, 17), 'text':'including GBM , .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(54, 0), 'end':(54, 21), 'text':'These mutations occur primarily in the adaptor binding domain ( ABD ) as well as the C2 helical and kinase domains -.'}, {'start':(55, 0), 'end':(55, 17), 'text':'Indeed , PIK3CA somatic nucleotide substitutions were detected in six of the 91 sequenced samples ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(56, 0), 'end':(56, 4), 'text':'Besides the 4 matching events'}, {'start':(56, 5), 'end':(56, 10), 'text':'already reported in the COSMIC database'}]}, {'start':(56, 11), 'end':(56, 35), 'text':'( http://www.sanger.ac.uk/genetics/CGP/cosmic/ ) , two novel in-frame deletions were detected in the ABD of PIK3CA ( " L10del " and " P17del " ) .'}]}, {'start':(57, 0), 'end':(57, 13), 'text':'Those deletions may disrupt interactions between p110alpha and its regulatory subunit , p85alpha .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'LeftToRight', 'children':[{'start':(58, 0), 'end':(58, 7), 'text':'Unlike PIK3CA , PIK3R1 has rarely been reported'}, {'start':(58, 8), 'end':(58, 12), 'text':'as mutated in cancers .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(59, 0), 'end':(59, 16), 'text':'Among the five reported PIK3R1 nucleotide substitutions in cancers , , one was in a glioblastoma .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(60, 0), 'end':(60, 13), 'text':'In our TCGA cohort , 9 PIK3R1 somatic mutations were detected among the 91'}, {'start':(60, 14), 'end':(60, 16), 'text':'sequenced GBMs .'}]}, {'start':(61, 0), 'end':(61, 9), 'text':'None of them was in samples with PIK3CA mutations .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(62, 0), 'end':(62, 10), 'text':'Of the nine mutations , eight lay within the intervening SH2'}, {'start':(62, 11), 'end':(62, 22), 'text':'( or iSH2 ) domain and four are 3-basepair in-frame deletions .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(63, 0), 'end':(63, 9), 'text':'In accord with the crystal structure of PI3 kinase ,'}, {'start':(63, 10), 'end':(63, 36), 'text':'which identifies the D560 and N564 amino acid residues in p85alpha as contact points with the N345 amino acid residue in the C2 domain of p110alpha ,'}]}, {'start':(63, 37), 'end':(63, 51), 'text':'the mutations detected in GBM cluster around those three amino acid residues ( ) ,'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(63, 52), 'end':(63, 57), 'text':'including a N345K mutation in PIK3CA'}, {'start':(63, 58), 'end':(63, 66), 'text':'( previously reported in colon and breast cancers )'}]}, {'start':(63, 67), 'end':(63, 79), 'text':'and two novel D560 mutations in PIK3R1 ( D560Y and N564K ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(64, 0), 'end':(64, 5), 'text':'We also identified an 18-basepair deletion'}, {'start':(64, 6), 'end':(64, 40), 'text':'spanning residues D560 to S565 ( DKRMNS ) in PIK3R1 ( ) in addition to three other novel deletions ( R574del , T576del , and W583del ) in proximity to the 3 key residues .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(65, 0), 'end':(65, 1), 'text':'We speculate'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(65, 2), 'end':(65, 8), 'text':'that spatial constraints due to these deletions'}, {'start':(65, 9), 'end':(65, 22), 'text':'might prevent inhibitory contact of p85alpha nSH2 with the helical domain of p110alpha ,'}]}, {'start':(65, 23), 'end':(65, 27), 'text':'causing constitutive PI3K activity .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(66, 0), 'end':(66, 2), 'text':'Taken together ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(66, 3), 'end':(66, 12), 'text':'the pattern of clustering of the mutations around key residues'}, {'start':(66, 13), 'end':(66, 21), 'text':'defined by the crystal structure of PI3K strongly suggest'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(66, 22), 'end':(66, 37), 'text':'that these novel PIK3R1 point mutations and insertions and deletions disrupt the important C2-iSH2 interaction ,'}, {'start':(66, 38), 'end':(66, 46), 'text':'relieving the inhibitory effect of p85alpha on p110alpha .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(67, 0), 'end':(67, 7), 'text':'MGMT methylation and MMR proficiency in post-treatment GBMs'}, {'start':(68, 0), 'end':(68, 28), 'text':'Cancer specific DNA methylation of CpG dinucleotides located in CpG islands within the promoters of 2,305 genes were measured relative to normal brain DNA ( ; Methods ) .'}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(69, 0), 'end':(69, 10), 'text':'The promoter methylation status of MGMT , a DNA repair enzyme'}, {'start':(69, 11), 'end':(69, 18), 'text':'that removes alkyl groups from guanine residues ,'}]}, {'start':(69, 19), 'end':(69, 28), 'text':'is associated with GBM sensitivity to alkylating agents , .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(70, 0), 'end':(70, 5), 'text':'Among the 91 sequenced cases ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(70, 6), 'end':(70, 14), 'text':'19 samples were found to contain MGMT promoter methylation'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(70, 15), 'end':(70, 26), 'text':'( including 13 of the 72 untreated and 6 of the 19'}, {'start':(70, 27), 'end':(70, 30), 'text':'treated cases ) .'}]}]}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(71, 0), 'end':(71, 6), 'text':'When juxtaposed with somatic mutation data ,'}, {'start':(71, 7), 'end':(71, 23), 'text':'an intriguing relationship between the hypermutator phenotype and MGMT methylation status emerged in the treated samples .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(72, 0), 'end':(72, 20), 'text':'Specifically , MGMT methylation was associated with a profound shift in the nucleotide substitution spectrum of treated GBMs ( ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(73, 0), 'end':(73, 3), 'text':'Among the treated samples'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(73, 4), 'end':(73, 6), 'text':'lacking MGMT methylation'}, {'start':(73, 7), 'end':(73, 12), 'text':'( n = 13 ) ,'}]}]}, {'start':(73, 13), 'end':(73, 19), 'text':'29 % ( 29 and 99 )'}]}, {'start':(73, 20), 'end':(73, 24), 'text':'of the validated somatic mutations'}]}, {'start':(73, 25), 'end':(73, 28), 'text':'occurred as G :'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(73, 29), 'end':(73, 32), 'text':'C to A :'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(73, 33), 'end':(73, 47), 'text':'T transitions in CpG dinucleotides ( characteristic of spontaneous deamination of methylated cytosines ) ,'}, {'start':(73, 48), 'end':(73, 64), 'text':'and a comparable 23 % ( 23 and 99 ) of all mutations occurred as G :'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(73, 65), 'end':(73, 68), 'text':'C to A :'}, {'start':(73, 69), 'end':(73, 75), 'text':'T transitions in non CpG dinucleotides .'}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(74, 0), 'end':(74, 9), 'text':'In contrast , in the treated samples with MGMT methylation'}, {'start':(74, 10), 'end':(74, 15), 'text':'( n = 6 ) ,'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(74, 16), 'end':(74, 25), 'text':'81 % of all mutations ( 146 and 181 )'}, {'start':(74, 26), 'end':(74, 33), 'text':'turned out to be of the G :'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(74, 34), 'end':(74, 37), 'text':'C to A :'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(74, 38), 'end':(74, 44), 'text':'T transition type in non CpG dinucleotides'}, {'start':(74, 45), 'end':(74, 59), 'text':'whereas only 4 % ( 8 and 181 ) of all mutations were G :'}]}, {'start':(74, 60), 'end':(74, 63), 'text':'C to A :'}]}, {'start':(74, 64), 'end':(74, 69), 'text':'T transition mutations within CpGs .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(75, 0), 'end':(75, 6), 'text':'That pattern is consistent with a failure'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(75, 7), 'end':(75, 11), 'text':'to repair alkylated guanine residues'}, {'start':(75, 12), 'end':(75, 15), 'text':'caused by treatment .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(76, 0), 'end':(76, 18), 'text':'In other words , MGMT methylation shifted the mutation spectrum of treated samples to a preponderance of G :'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(76, 19), 'end':(76, 22), 'text':'C to A :'}, {'start':(76, 23), 'end':(76, 29), 'text':'T transition at non CpG sites .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(77, 0), 'end':(77, 21), 'text':'Significantly , the mutational spectra in the mismatch repairs ( MMR ) genes themselves reflected MGMT methylation status and treatment consequences .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(78, 0), 'end':(78, 5), 'text':'All seven mutations in MMR genes'}, {'start':(78, 6), 'end':(78, 9), 'text':'found in six MGMT'}]}, {'start':(78, 10), 'end':(78, 11), 'text':'methylated hypermutated'}]}, {'start':(78, 12), 'end':(78, 19), 'text':'( treated ) tumors occurred as G :'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(78, 20), 'end':(78, 23), 'text':'C to A :'}, {'label':'contrast', 'direction':'None', 'children':[{'start':(78, 24), 'end':(78, 30), 'text':'T mutations at non CpG sites ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(78, 31), 'end':(78, 36), 'text':'while neither MMR mutations in non'}, {'start':(78, 37), 'end':(78, 44), 'text':'methylated hypermutated tumors was of this characteristic .'}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(79, 0), 'end':(79, 4), 'text':'Hence , these data show'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(79, 5), 'end':(79, 18), 'text':'that MMR deficiency and MGMT methylation together , in the context of treatment ,'}, {'start':(79, 19), 'end':(79, 43), 'text':'exert a powerful influence on the overall frequency and pattern of somatic point mutations in GBM tumors , an observation of potential clinical importance .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(80, 0), 'end':(80, 4), 'text':'Integrative analyses define core pathways'}, {'start':(80, 5), 'end':(80, 8), 'text':'required for GBM pathogenesis'}]}, {'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(81, 0), 'end':(81, 15), 'text':'To begin to construct an integrated view of common genetic alterations in the GBM genome ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(81, 16), 'end':(81, 21), 'text':'we mapped the unequivocal genetic alterations'}, {'start':(81, 22), 'end':(81, 33), 'text':'-- validated somatic nucleotide substitutions , homozygous deletions and focal amplifications --'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(81, 34), 'end':(81, 36), 'text':'onto major pathways'}, {'start':(81, 37), 'end':(81, 40), 'text':'implicated in GBM .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(82, 0), 'end':(82, 11), 'text':'That analysis identified a highly interconnected network of aberrations ( ) ,'}, {'start':(82, 12), 'end':(82, 16), 'text':'including three major pathways :'}]}, {'start':(82, 17), 'end':(82, 35), 'text':'receptor tyrosine kinases ( RTKs ) signaling , and the p53 and RB tumor suppressor pathways ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(83, 0), 'end':(83, 29), 'text':'By copy number data alone , 66 % , 70 % and 59 % of the 206 samples harbored somatic alterations of the RB , TP53 and RTK pathways ,'}, {'start':(83, 30), 'end':(83, 33), 'text':'respectively ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(84, 0), 'end':(84, 3), 'text':'In the 91 samples'}, {'start':(84, 4), 'end':(84, 11), 'text':'for which there was also sequencing data ,'}]}, {'start':(84, 12), 'end':(84, 31), 'text':'the frequencies of somatic alterations increased to 87 % , 78 % and 88 % , respectively ( ) .'}]}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(85, 0), 'end':(85, 45), 'text':'There was a statistical tendency toward mutual exclusivity of alterations of components within each pathway ( p-values of 9.3 x10 -10 , 2.5 x10 -13 , and 0.022 , respectively for the p53 , RB , and RTK pathways ; ) , consistent with the thesis'}, {'start':(85, 46), 'end':(85, 61), 'text':'that deregulation of one component in the pathway relieves the selective pressure for additional ones .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(86, 0), 'end':(86, 8), 'text':'However , we observed a greater than random chance'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(86, 9), 'end':(86, 15), 'text':'( one tailed p = 0.0018 )'}, {'start':(86, 16), 'end':(86, 34), 'text':'that a given sample harbors at least one aberrant gene from each of the three pathways ( ) .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(87, 0), 'end':(87, 13), 'text':'In fact , 74 % harbored aberrations in all three pathways , a pattern'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(87, 14), 'end':(87, 14), 'text':'suggesting'}, {'start':(87, 15), 'end':(87, 28), 'text':'that deregulation of the three pathways is a core requirement for glioblastoma pathogenesis .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(88, 0), 'end':(88, 35), 'text':'Besides frequent deletions and mutations of the PTEN lipid phosphatase tumor suppressor gene , 86 % of the GBM samples harbored at least one genetic event in the core RTK and PI3K pathway ( ) .'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(89, 0), 'end':(89, 17), 'text':'In addition to EGFR and ERBB , PDGFRA ( 13 % ) and MET ( 4 % )'}, {'start':(89, 18), 'end':(89, 23), 'text':'showed frequent aberrations ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(90, 0), 'end':(90, 31), 'text':'10 of the 91 sequenced samples have amplifications or point mutations in at least two of the four RTKs catalogued ( EGFR , ERBB2 , PDGFRA and MET ) ( ) ,'}, {'start':(90, 32), 'end':(90, 42), 'text':'suggesting genomic activation can be a mechanism for co-activated RTKs .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(91, 0), 'end':(91, 30), 'text':'Inactivation of the p53 pathway occurred in the form of ARF deletions ( 55 % ) , amplifications of MDM2 ( 11 % ) and MDM4 ( 4 % ) ,'}, {'start':(91, 31), 'end':(91, 38), 'text':'in addition to mutations of p53 itself .'}]}, {'label':'contrast', 'direction':'None', 'children':[{'start':(92, 0), 'end':(92, 37), 'text':'Among 91 sequenced samples ( ) , genetic lesions in TP53 were mutually exclusive of those in MDM2 or MDM4 ( odds ratios of 0.00 for both ; p = 0.02 and 0.068 , respectively ; ) ,'}, {'start':(92, 38), 'end':(92, 44), 'text':'but not of those in ARF .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(93, 0), 'end':(93, 14), 'text':'In fact , 10 of the 32 tumors with TP53 mutations also deleted ARF ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(93, 15), 'end':(93, 15), 'text':'suggesting'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(93, 16), 'end':(93, 22), 'text':'that homozygous deletion of the CDKN2A locus'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(93, 23), 'end':(93, 23), 'text':'('}, {'start':(93, 24), 'end':(93, 41), 'text':'which encodes both p16 INK4A and ARF ) was at least in part driven by p16 INK4A .'}]}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(94, 0), 'end':(94, 4), 'text':'Among the 77 % samples'}, {'start':(94, 5), 'end':(94, 11), 'text':'harboring RB pathway aberrations ( ) ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(94, 12), 'end':(94, 34), 'text':'the most common event was deletion of the CDKN2A and CDKN2B locus on chromosome 9p21 ( 55 % and 53 % ) ,'}, {'start':(94, 35), 'end':(94, 46), 'text':'followed by amplification of the CDK4 locus ( 14 % ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(95, 0), 'end':(95, 17), 'text':'Although copy number alterations in the CDK and RB pathway members can co-occur in the same tumor ,'}, {'start':(95, 18), 'end':(95, 40), 'text':'all nine samples with RB1 nucleotide substitutions ( ) lacked CDKN2A and B deletion or other copy number alterations in the pathway ,'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(95, 41), 'end':(95, 41), 'text':'suggesting'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(95, 42), 'end':(95, 56), 'text':'that inactivation of RB1 by nucleotide substitution , in contrast to copy number loss ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(95, 57), 'end':(95, 65), 'text':'obviates the genetic pressure for activation of upstream cyclin'}, {'start':(95, 66), 'end':(95, 70), 'text':'and cyclin dependent kinases .'}]}]}]}]}, {'start':(96, 0), 'end':(96, 0), 'text':'.'}]}]}]}]}]}]}]}]}]}]}
0	1	{'start':(0, 0), 'end':(0, 9), 'text':'Comprehensive genomic characterization defines human glioblastoma genes and core pathways'}
148	236	{'label':'topic-change', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 3), 'text':'The Cancer Genome Atlas'}, {'start':(0, 4), 'end':(0, 8), 'text':'( TCGA ) Research Network'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(1, 0), 'end':(1, 2), 'text':'Tissue Source Sites'}, {'label':'joint', 'direction':'None', 'children':[{'start':(2, 0), 'end':(2, 3), 'text':'Duke University Medical School'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 20), 'text':'Roger McLendon ( 6 ) , Allan Friedman ( 7 ) , Darrell Bigner ( 6 ) , Emory University :'}, {'start':(3, 21), 'end':(3, 52), 'text':'Erwin G Van Meir ( 45,46,47 ) , Daniel J Brat ( 47,48 ) , Gena Marie Mastrogianakis ( 45 ) , Jeffrey J Olson ( 45,46,47 ) Henry Ford Hospital :'}]}, {'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(3, 53), 'end':(3, 58), 'text':'Tom Mikkelsen ( 8 ) ,'}, {'start':(3, 59), 'end':(3, 69), 'text':'Norman Lehman ( 50 ) , MD Anderson Cancer Center :'}]}]}, {'start':(3, 70), 'end':(3, 94), 'text':'Ken Aldape ( 10 ) , W.K. Alfred Yung ( 11 ) , Oliver Bogler ( 12 ) , University of California San Francisco :'}]}, {'start':(3, 95), 'end':(3, 106), 'text':'Scott VandenBerg ( 9 ) , Mitchel Berger ( 51 ) ,'}]}, {'start':(3, 107), 'end':(3, 111), 'text':'Michael Prados ( 51 )'}]}, {'label':'textual-organization', 'direction':'None', 'children':[{'start':(4, 0), 'end':(4, 2), 'text':'Genome Sequencing Centers'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 3), 'text':'Baylor College of Medicine'}, {'label':'joint', 'direction':'None', 'children':[{'start':(6, 0), 'end':(6, 153), 'text':'Donna Muzny ( 34 ) , Margaret Morgan ( 34 ) , Steve Scherer ( 34 ) , Aniko Sabo ( 34 ) , Lynn Nazareth ( 34 ) , Lora Lewis ( 34 ) , Otis Hall ( 34 ) , Yiming Zhu ( 34 ) , Yanru Ren ( 34 ) , Omar Alvi ( 34 ) , Jiqiang Yao ( 34 ) , Alicia Hawes ( 34 ) , Shalini Jhangiani ( 34 ) , Gerald Fowler ( 34 ) , Anthony San Lucas ( 34 ) , Christie Kovar ( 34 ) , Andrew Cree ( 34 ) , Huyen Dinh ( 34 ) , Jireh Santibanez ( 34 ) , Vandita Joshi ( 34 ) , Manuel L. Gonzalez-Garay ( 34 ) , Christopher A. Miller ( 34,36 ) , Aleksandar Milosavljevic ( 34,36,37 ) , Larry Donehower ( 35 ) , David A. Wheeler ( 34 ) ,'}, {'start':(6, 154), 'end':(6, 167), 'text':'Richard A. Gibbs ( 34 ) , Broad Institute of MIT and Harvard :'}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 168), 'end':(6, 251), 'text':'Kristian Cibulskis ( 52 ) , Carrie Sougnez ( 53 ) , Tim Fennell ( 54 ) , Scott Mahan ( 59 ) , Jane Wilkinson ( 55 ) , Liuda Ziaugra ( 56 ) , Robert Onofrio ( 56 ) , Toby Bloom ( 57 ) , Rob Nicol ( 58 ) , Kristin Ardlie ( 59 ) , Jennifer Baldwin ( 55 ) , Stacey Gabriel ( 56 ) , Eric Lander ( 4,60,61 ) , Washington University in Saint Louis :'}, {'label':'joint', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(6, 252), 'end':(6, 315), 'text':'Li Ding ( 19 ) , Robert S. Fulton ( 19 ) , Michael D. McLellan ( 19 ) , John Wallis ( 19 ) , David E. Larson ( 19 ) , Xiaoqi Shi ( 19 ) , Rachel Abbott ( 19 ) , Lucinda Fulton ( 19 ) , Ken Chen ( 19 ) , Daniel C. Koboldt ( 19 ) ,'}, {'start':(6, 316), 'end':(6, 466), 'text':'Michael C. Wendl ( 19 ) , Rick Meyer ( 19 ) , Yuzhu Tang ( 19 ) , Ling Lin ( 19 ) , John R. Osborne ( 19 ) , Brian H. Dunford-Shore ( 19 ) , Tracie L. Miner ( 19 ) , Kim Delehaunty ( 19 ) , Chris Markovic ( 19 ) , Gary Swift ( 19 ) , William Courtney ( 19 ) , Craig Pohl ( 19 ) , Scott Abbott ( 19 ) , Amy Hawkins ( 19 ) , Shin Leong ( 19 ) , Carrie Haipek ( 19 ) , Heather Schmidt ( 19 ) , Maddy Wiechert ( 19 ) , Tammi Vickery ( 19 ) , Sacha Scott ( 19 ) , David J. Dooling ( 19 ) , Asif Chinwalla ( 19 ) , George M. Weinstock ( 19 ) , Elaine R. Mardis ( 19 ) ,'}]}, {'label':'textual-organization', 'direction':'None', 'children':[{'start':(6, 467), 'end':(6, 472), 'text':'Richard K. Wilson ( 19 )'}, {'label':'textual-organization', 'direction':'None', 'children':[{'start':(7, 0), 'end':(7, 3), 'text':'Cancer Genome Characterization Centers'}, {'label':'textual-organization', 'direction':'None', 'children':[{'start':(8, 0), 'end':(8, 5), 'text':'Broad Institute and Dana-Farber Cancer Institute'}, {'label':'textual-organization', 'direction':'None', 'children':[{'start':(9, 0), 'end':(9, 153), 'text':'Gad Getz ( 4 ) , Wendy Winckler ( 4,5 ) , Roel G.W. Verhaak ( 4,5 ) , Michael S. Lawrence ( 4 ) , Michael O\'Kelly ( 4 ) , Jim Robinson ( 4 ) , Gabriele Alexe ( 4 ) , Rameen Beroukhim ( 4,5 ) , Scott Carter ( 4 ) , Derek Chiang ( 4,5 ) , Josh Gould ( 4 ) , Supriya Gupta ( 4 ) , Josh Korn ( 4 ) , Craig Mermel ( 4,5 ) , Jill Mesirov ( 4 ) , Stefano Monti ( 4 ) , Huy Nguyen ( 4 ) , Melissa Parkin ( 4 ) , Michael Reich ( 4 ) , Nicolas Stransky ( 4 ) , Barbara A. Weir ( 4,5 ) , Levi Garraway ( 4,5 ) , Todd Golub ( 4,62 ) , Matthew Meyerson ( 4,5 ) Harvard Medical School and Dana-Farber Cancer Institute :'}, {'label':'textual-organization', 'direction':'None', 'children':[{'start':(9, 154), 'end':(9, 252), 'text':'Lynda Chin ( 1,2,3 ) , Alexei Protopopov ( 2 ) , Jianhua Zhang ( 2 ) , Ilana Perna ( 2 ) , Sandy Aronson ( 21 ) , Narayan Sathiamoorthy ( 21 ) , Georgia Ren ( 2 ) , Jun Yao ( 2 ) , Hyunsoo Kim ( 21 ) , Sek Won Kong ( 23,71 ) Yonghong Xiao ( 2 ) , Isaac S. Kohane ( 21,22,23 ) , Jon Seidman ( 63 ) , Peter J. Park ( 21,22,23 ) , Raju Kucherlapati ( 21 ) John Hopkins and University of Southern California :'}, {'label':'textual-organization', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(9, 253), 'end':(9, 259), 'text':'Peter W. Laird ( 49 ) ,'}, {'start':(9, 260), 'end':(9, 326), 'text':'Leslie Cope ( 43 ) , James G. Herman ( 42 ) , Daniel J. Weisenberger ( 49 ) , Fei Pan ( 49 ) , David Van Den Berg ( 49 ) , Leander Van Neste ( 44 ) , Joo Mi Yi ( 42 ) , Kornel E. Schuebel ( 42 ) , Stephen B. Baylin ( 42 ) HudsonAlpha Institute and Stanford University :'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(9, 327), 'end':(9, 377), 'text':'Devin M. Absher ( 64 ) , Jun Z. Li ( 70 ) , Audrey Southwick ( 32 ) , Shannon Brady ( 32 ) , Amita Aggarwal ( 32 ) , Tisha Chung ( 32 ) , Gavin Sherlock ( 32 ) , James D. Brooks ( 33 ) ,'}, {'start':(9, 378), 'end':(9, 388), 'text':'Richard M. Myers ( 64 ) Lawrence Berkeley National Laboratory :'}]}]}, {'label':'textual-organization', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(9, 389), 'end':(9, 427), 'text':'Paul T. Spellman ( 28 ) , Elizabeth Purdom ( 29 ) , Lakshmi R. Jakkula ( 28 ) , Anna V. Lapuk ( 28 ) , Henry Marr ( 28 ) , Shannon Dorton ( 28 ) ,'}, {'start':(9, 428), 'end':(9, 530), 'text':'Yoon Gi Choi ( 30 ) , Ju Han ( 28 ) , Amrita Ray ( 28 ) , Victoria Wang ( 29 ) , Steffen Durinck ( 28 ) , Mark Robinson ( 31 ) , Nicholas J. Wang ( 28 ) , Karen Vranizan ( 30 ) , Vivian Peng ( 30 ) , Eric Van Name ( 30 ) , Gerald V. Fontenay ( 28 ) , John Ngai ( 30 ) , John G. Conboy ( 28 ) , Bahram Parvin ( 28 ) , Heidi S. Feiler ( 28 ) , Terence P. Speed ( 29,31 ) ,'}]}, {'start':(9, 531), 'end':(9, 542), 'text':'Joe W. Gray ( 28 ) Memorial Sloan Kettering Cancer Center :'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(9, 543), 'end':(9, 623), 'text':'Cameron Brennan ( 24 ) , Nicholas D. Socci ( 25 ) , Adam Olshen ( 65 ) , Barry S. Taylor ( 25,26 ) , Alex Lash ( 25 ) , Nikolaus Schultz ( 25 ) , Boris Reva ( 25 ) , Yevgeniy Antipin ( 25 ) , Alexey Stukalov ( 25 ) , Benjamin Gross ( 25 ) , Ethan Cerami ( 25 ) , Wei Qing Wang ( 25 ) , Li-Xuan Qin ( 65 ) ,'}, {'start':(9, 624), 'end':(9, 630), 'text':'Venkatraman E. Seshan ( 65 ) ,'}]}]}, {'start':(9, 631), 'end':(9, 679), 'text':'Liliana Villafania ( 66 ) , Magali Cavatore ( 66 ) , Laetitia Borsu ( 27 ) , Agnes Viale ( 66 ) , William Gerald ( 27 ) , Chris Sander ( 25 ) , Marc Ladanyi ( 27 ) University of North Carolina , Chapel Hill :'}]}, {'label':'textual-organization', 'direction':'None', 'children':[{'start':(9, 680), 'end':(9, 693), 'text':'Charles M. Perou ( 38,39 ) , D. Neil Hayes ( 40 ) ,'}, {'label':'textual-organization', 'direction':'None', 'children':[{'start':(9, 694), 'end':(9, 730), 'text':'Michael D. Topal ( 39 ) , Katherine A. Hoadley ( 38 ) , Yuan Qi ( 40 ) , Sai Balu ( 41 ) , Yan Shi ( 41 ) , George Wu ( 41 )'}, {'label':'textual-organization', 'direction':'None', 'children':[{'start':(10, 0), 'end':(10, 2), 'text':'Biospecimen Core Resource'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(11, 0), 'end':(11, 5), 'text':'Robert Penny ( 17 ) ,'}, {'label':'joint', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(11, 6), 'end':(11, 11), 'text':'Michael Bittner ( 67 ) ,'}, {'start':(11, 12), 'end':(11, 17), 'text':'Troy Shelton ( 17 ) ,'}]}, {'start':(11, 18), 'end':(11, 23), 'text':'Elizabeth Lenkiewicz ( 17 ) ,'}]}, {'start':(11, 24), 'end':(11, 29), 'text':'Scott Morris ( 17 ) ,'}]}]}, {'start':(11, 30), 'end':(11, 35), 'text':'Debbie Beasley ( 17 ) ,'}]}, {'start':(11, 36), 'end':(11, 37), 'text':'Sheri Sanders'}]}, {'start':(11, 38), 'end':(11, 40), 'text':'( 17 )'}]}, {'start':(12, 0), 'end':(12, 0), 'text':'Data'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 1), 'end':(12, 2), 'text':'Coordinating Center'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 5), 'text':'Ari Kahn ( 13 ) ,'}, {'start':(13, 6), 'end':(13, 11), 'text':'Robert Sfeir ( 13 ) ,'}]}, {'start':(13, 12), 'end':(13, 23), 'text':'Jessica Chen ( 13 ) , David Nassau ( 13 ) ,'}]}, {'start':(13, 24), 'end':(13, 29), 'text':'Larry Feng ( 13 ) ,'}]}, {'start':(13, 30), 'end':(13, 35), 'text':'Erin Hickey ( 13 ) ,'}]}, {'start':(13, 36), 'end':(13, 41), 'text':'Carl Schaefer ( 68 ) ,'}]}, {'start':(13, 42), 'end':(13, 47), 'text':'Subha Madhavan ( 68 ) ,'}]}, {'start':(13, 48), 'end':(13, 52), 'text':'Ken Buetow ( 68 )'}]}, {'label':'textual-organization', 'direction':'None', 'children':[{'start':(14, 0), 'end':(14, 1), 'text':'Project Teams'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 49), 'text':'National Cancer Institute Anna Barker ( 16 ) , Daniela Gerhard ( 16 ) , Joseph Vockley ( 16 ) , Martin Ferguson ( 18 ) , Carolyn Compton ( 16 ) , Jim Vaught ( 16 ) , Peter Fielding ( 16 ) National Human Genome Research Institute :'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 50), 'end':(15, 55), 'text':'Francis Collins ( 15 ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 56), 'end':(15, 61), 'text':'Peter Good ( 15 ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 62), 'end':(15, 67), 'text':'Mark Guyer ( 15 ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 68), 'end':(15, 73), 'text':'Brad Ozenberger ( 15 ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 74), 'end':(15, 75), 'text':'Jane Peterson'}, {'start':(15, 76), 'end':(15, 85), 'text':'( 15 ) & Elizabeth Thomson ( 15 ) .'}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 3), 'text':'Affiliations for participants :'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 0), 'end':(17, 16), 'text':'1 ) Department of Medical Oncology , Dana-Farber Cancer Institute ; Boston , Massachusetts 02115 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 0), 'end':(18, 25), 'text':'2 ) Center for Applied Cancer Science of the Belfer Institute for Innovative Cancer Science , Dana-Farber Cancer Institute , Boston , Massachusetts 02115 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 0), 'end':(19, 15), 'text':'3 ) Department of Dermatology , Harvard Medical School , Boston , Massachusetts 02115 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 22), 'text':'4 ) The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University , Cambridge , MA , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 16), 'text':'5 ) Department of Medical Oncology , Dana-Farber Cancer Institute , Boston , Massachusetts 02115 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 0), 'end':(22, 17), 'text':'6 ) Department of Pathology , Duke University Medical Center , Durham , North Carolina 27710 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 0), 'end':(23, 17), 'text':'7 ) Department of Surgery , Duke University Medical Center , Durham , North Carolina 27710 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 0), 'end':(24, 16), 'text':'8 ) Departments of Neurological Surgery , Henry Ford Hospital , Detroit , MI 48202 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 0), 'end':(25, 18), 'text':'9 ) Department of Pathology , University of California San Francisco , San Francisco , California 94143 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 0), 'end':(26, 19), 'text':'10 ) Department of Pathology , University of Texas M.D. Anderson Cancer Center , Houston , Texas 77030 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 0), 'end':(27, 19), 'text':'11 ) Department of Neuro-Oncology , University of Texas M.D. Anderson Cancer Center , Houston , Texas 77030 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 0), 'end':(28, 19), 'text':'12 ) Department of Neurosurgery , University of Texas M.D. Anderson Cancer Center , Houston , Texas 77030 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(29, 0), 'end':(29, 10), 'text':'13 ) SRA International , Fairfax , VA 22033 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 0), 'end':(30, 19), 'text':'14 ) Center for Biomedical Informatics and Informational Technology , National Cancer Institute , Rockville , Maryland 20852 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(31, 0), 'end':(31, 18), 'text':'15 ) National Human Genome Research Institute , National Institutes of Health , Bethesda , Maryland 20892 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 0), 'end':(32, 16), 'text':'16 ) National Cancer Institute , National Institutes of Health , Bethesda , Maryland 20892 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(33, 0), 'end':(33, 10), 'text':'17 ) International Genomics Consortium , Phoenix , AZ 85004 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(34, 0), 'end':(34, 9), 'text':'18 ) MLF Consulting , Arlington , MA 02474 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(35, 0), 'end':(35, 25), 'text':'19 ) The Genome Center at Washington University , Department of Genetics , Washington University School of Medicine , St. Louis , Missouri 63108 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(36, 0), 'end':(36, 17), 'text':'20 ) The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins , Baltimore , Maryland 21231 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(37, 0), 'end':(37, 17), 'text':'21 ) Harvard Medical School-Partners HealthCare Center for Genetics and Genomics , Boston , MA 02115 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(38, 0), 'end':(38, 16), 'text':'22 ) Center for Biomedical Informatics , Harvard Medical School , Boston , MA 02115 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(39, 0), 'end':(39, 13), 'text':'23 ) Informatics Program , Children \'s Hospital , Boston , MA 02115 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(40, 0), 'end':(40, 17), 'text':'24 ) Department of Neurosurgery , Memorial-Sloan Kettering Cancer Center , New York , NY 10065 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(41, 0), 'end':(41, 17), 'text':'25 ) Computational Biology Center , Memorial Sloan Kettering Cancer Center , New York , NY 10065 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(42, 0), 'end':(42, 21), 'text':'26 ) Department of Physiology and Biophysics , Weill Cornell Graduate School of Medical Sciences , New York , NY 10065 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(43, 0), 'end':(43, 22), 'text':'27 ) Department of Pathology , Human Oncology and Pathogenesis Program , Memorial Sloan Kettering Cancer Center , New York , NY 10065'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(44, 0), 'end':(44, 16), 'text':'28 ) Life Sciences Division , Lawrence Berkeley National Laboratory , Berkeley , California 94720 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(45, 0), 'end':(45, 17), 'text':'29 ) Department of Statistics , University of California at Berkeley , Berkeley , California 95720 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(46, 0), 'end':(46, 20), 'text':'30 ) Department of Molecular and Cellular Biology , University of California at Berkeley , Berkeley , California 95720 , USA'}, {'start':(47, 0), 'end':(47, 14), 'text':'31 ) Walter and Eliza Hall Institute , Parkville , Vic 3052 , Australia .'}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(48, 0), 'end':(48, 17), 'text':'32 ) Department of Genetics , Stanford University School of Medicine , Stanford , California 94305 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(49, 0), 'end':(49, 17), 'text':'33 ) Department of Urology , Stanford University School of Medicine , Stanford , California 94305 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(50, 0), 'end':(50, 17), 'text':'34 ) Human Genome Sequencing Center , Baylor College of Medicine , Houston , Texas 77030 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(51, 0), 'end':(51, 24), 'text':'35 ) Department of Molecular Virology and Microbiology , Human Genome Sequencing Center , Baylor College of Medicine , Houston , Texas 77030 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(52, 0), 'end':(52, 23), 'text':'36 ) Graduate Program in Structural and Computational Biology and Molecular Biophysics , Baylor College of Medicine , Houston , TX 77030 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(53, 0), 'end':(53, 19), 'text':'37 ) Department of Molecular and Human Genetics , Baylor College of Medicine , Houston , TX 77030 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(54, 0), 'end':(54, 25), 'text':'38 ) Department of Genetics , Lineberger Comprehensive Cancer Center , University of North Carolina at Chapel Hill , Chapel Hill , NC 27599 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(55, 0), 'end':(55, 28), 'text':'39 ) Department of Pathology and Laboratory Medicine , Lineberger Comprehensive Cancer Center , University of North Carolina at Chapel Hill , Chapel Hill , NC 27599 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(56, 0), 'end':(56, 31), 'text':'40 ) Department of Internal Medicine , Division of Medical Oncology , Lineberger Comprehensive Cancer Center , University of North Carolina at Chapel Hill , Chapel Hill , NC 27599 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(57, 0), 'end':(57, 21), 'text':'41 ) Lineberger Comprehensive Cancer Center , University of North Carolina at Chapel Hill , Chapel Hill , NC 27599 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(58, 0), 'end':(58, 22), 'text':'42 ) Cancer Biology Division , The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University , Baltimore , Maryland 21231 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(59, 0), 'end':(59, 24), 'text':'43 ) Biometry and Clinical Trials Division , The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University , Baltimore , Maryland 21231 , USA'}, {'start':(60, 0), 'end':(60, 20), 'text':'44 ) Department of Molecular Biotechnology , Faculty of Bioscience and Engineering , Ghent University , Ghent B-9000 , Belgium .'}]}]}]}]}]}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(61, 0), 'end':(61, 17), 'text':'45 ) Department of Neurosurgery , Emory University School of Medicine , Atlanta , Georgia 30322 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(62, 0), 'end':(62, 20), 'text':'46 ) Department of Hematology and Medical Oncology , Emory University School of Medicine , Atlanta , Georgia 30322 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(63, 0), 'end':(63, 17), 'text':'47 ) Winship Cancer Institute , Emory University School of Medicine , Atlanta , Georgia 30322 , USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(64, 0), 'end':(64, 20), 'text':'48 ) Department of Pathology and Laboratory Medicine , Emory University School of Medicine , Atlanta , Georgia 30322 , USA'}, {'start':(65, 0), 'end':(65, 20), 'text':'49 ) University of Southern California Epigenome Center , University of Southern California , Los Angeles , California 90089 , USA'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(66, 0), 'end':(66, 14), 'text':'50 ) Department of Pathology , Henry Ford Hospital , Detroit , MI 48202 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(67, 0), 'end':(67, 17), 'text':'51 ) Department of Neurosurgery , University of California San Francisco , San Francisco , CA 94143 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(68, 0), 'end':(68, 29), 'text':'52 ) Medical Sequencing Analysis and Informatics , The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University , Cambridge , MA , 02142 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(69, 0), 'end':(69, 30), 'text':'53 ) Cancer Genome & Medical Resequencing Projects , The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University , Cambridge , MA , 02142 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(70, 0), 'end':(70, 27), 'text':'54 ) Directed Sequencing Informatics , The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University , Cambridge , MA , 02142 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(71, 0), 'end':(71, 26), 'text':'55 ) Sequencing Platform , The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University , Cambridge , MA , 02142 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(72, 0), 'end':(72, 27), 'text':'56 ) Genetic Analysis Platform , The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University , Cambridge , MA , 02142 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(73, 0), 'end':(73, 27), 'text':'57 ) Sequencing Platform Informatics , The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University , Cambridge , MA , 02142 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(74, 0), 'end':(74, 27), 'text':'58 ) Sequencing Platform Production , The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University , Cambridge , MA , 02142 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(75, 0), 'end':(75, 27), 'text':'59 ) Biological Samples Platform , The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University , Cambridge , MA , 02142 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(76, 0), 'end':(76, 18), 'text':'60 ) Department of Biology , Institute of Massachusetts Institute of Technology , Cambridge , MA , 02142 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(77, 0), 'end':(77, 15), 'text':'61 ) Department of Systems Biology , Harvard University , Boston , MA , 02115 USA'}, {'start':(78, 0), 'end':(78, 14), 'text':'62 ) Department of Pediatric Oncology , Dana-Farber Cancer Institute , Boston MA 02115 USA'}]}]}]}]}]}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(79, 0), 'end':(79, 15), 'text':'63 ) Department of Genetics , Harvard Medical School , Boston , MA , 02115 USA'}, {'start':(80, 0), 'end':(80, 11), 'text':'64 ) HudsonAlpha Institute for Biotechnology , Huntsville , AL 35806 USA'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(81, 0), 'end':(81, 19), 'text':'65 ) Department of Epidemiology and Biostatistics , Memorial Sloan Kettering Cancer Center , New York , NY 10065 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(82, 0), 'end':(82, 17), 'text':'66 ) Genomics Core Laboratory , Memorial Sloan Kettering Cancer Center , New York , NY 10065 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(83, 0), 'end':(83, 15), 'text':'67 ) Computational Biology Division , Translational Genomics Research Institute , Phoenix , AZ 85004 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(84, 0), 'end':(84, 18), 'text':'68 ) Center For Biomedical Informatics and Information Technology , National Cancer Institute , Rockville , MD 20852 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(85, 0), 'end':(85, 18), 'text':'69 ) Department of Bioinformatics and Computational Biology , M.D. Anderson Cancer Center , Houston , TX 77030 USA'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(86, 0), 'end':(86, 16), 'text':'70 ) Department of Human Genetics , University of Michigan , Ann Arbor , MI 48109 USA'}, {'start':(87, 0), 'end':(87, 14), 'text':'71 ) Department of Cardiology , Children \'s Hospital , Boston , MA 02115 USA'}]}]}]}]}]}]}]}]}]}]}
1	7	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 13), 'text':'Human cancer cells typically harbor multiple chromosomal aberrations , nucleotide substitutions and epigenetic modifications'}, {'start':(0, 14), 'end':(0, 18), 'text':'that drive malignant transformation .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(1, 0), 'end':(1, 24), 'text':'The Cancer Genome Atlas ( TCGA ) pilot project aims to assess the value of large-scale multidimensional analysis of these molecular characteristics in human cancer'}, {'start':(1, 25), 'end':(1, 35), 'text':'and to provide the data rapidly to the research community .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 45), 'text':'Here , we report the interim integrative analysis of DNA copy number , gene expression and DNA methylation aberrations in 206 glioblastomas ( GBM ) , the most common type of adult brain cancer , and nucleotide sequence aberrations in 91 of the 206 GBMs .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(3, 0), 'end':(3, 14), 'text':'This analysis provides new insights into the roles of ERBB2 , NF1 and TP53 ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(3, 15), 'end':(3, 26), 'text':'uncovers frequent mutations of the PI3 kinase regulatory subunit gene PIK3R1 ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 27), 'end':(3, 34), 'text':'and provides a network view of the pathways'}, {'start':(3, 35), 'end':(3, 41), 'text':'altered in the development of GBM .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 38), 'text':'Furthermore , integration of mutation , DNA methylation and clinical treatment data reveals a link between MGMT promoter methylation and a hypermutator phenotype consequent to mismatch repair deficiency in treated glioblastomas , an observation with potential clinical implications .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 11), 'text':'Together , these findings establish the feasibility and power of TCGA ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(5, 12), 'end':(5, 12), 'text':'demonstrating'}, {'start':(5, 13), 'end':(5, 25), 'text':'that it can rapidly expand knowledge of the molecular basis of cancer .'}]}]}]}]}
113	136	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'Discussion'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(1, 0), 'end':(1, 5), 'text':'In establishing this pilot program ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(1, 6), 'end':(1, 21), 'text':'TCGA has developed important principles in biospecimen banking and collection ( manuscript in preparation ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 22), 'end':(1, 25), 'text':'and established the infrastructure'}, {'start':(1, 26), 'end':(1, 34), 'text':'that will serve similar efforts in the future .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(2, 0), 'end':(2, 6), 'text':'Although it ensured high quality data ,'}, {'label':'explanation', 'direction':'LeftToRight', 'children':[{'start':(2, 7), 'end':(2, 18), 'text':'the stringent biospecimen selection criteria may have introduced a degree of bias'}, {'start':(2, 19), 'end':(2, 31), 'text':'because small samples and samples with high levels of necrosis were excluded .'}]}]}, {'start':(3, 0), 'end':(3, 16), 'text':'Nonetheless , the clinical parameters of this cohort are similar to other published cohorts ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 14), 'text':'The integrated analyses of multi-dimensional genomic data from complementary technology platforms have proved informative .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 35), 'text':'In addition to pinpointing deregulation of RB , p53 and RTK/RAS/PI3K pathways as obligatory events in most , and perhaps all , GBM tumors , the patterns of mutations may also inform future therapeutic decisions .'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(6, 0), 'end':(6, 5), 'text':'It would be reasonable to speculate'}, {'start':(6, 6), 'end':(6, 46), 'text':'that patients with deletions or inactivating mutations in CDKN2A or CDKN2C or patients with amplifications of CDK4 and CDK6 would be candidates for treatment with CDK inhibitors , a strategy not likely to be effective in patients with RB1 mutation .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'None', 'children':[{'start':(7, 0), 'end':(7, 25), 'text':'Similarly , patients with PTEN deletions or activating mutations in PIK3CA or PIK3R might be expected to benefit from a PI3 kinase or PDK1 inhibitor ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 26), 'end':(7, 27), 'text':'while tumors'}, {'start':(7, 28), 'end':(7, 45), 'text':'in which the PI3 kinase pathway is altered by AKT3 amplification might prove refractory to those modalities .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 11), 'text':'The presence of genomic co-amplification reinforces the recent report of multiple phosphorylated'}, {'start':(8, 12), 'end':(8, 20), 'text':'( activated ) RTKs in individual GBM specimens ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 21), 'end':(8, 23), 'text':'suggesting a way'}, {'start':(8, 24), 'end':(8, 35), 'text':'to tailor anti-RTK therapeutic cocktails to specific patterns of RTK mutation .'}]}]}, {'start':(9, 0), 'end':(9, 17), 'text':'In addition , combination anti-RTK therapy might synergize with downstream inhibition of PI3K or cell cycle mediators .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 20), 'text':'In contrast , GBMs with NF1 mutations might benefit from a RAF or MEK inhibitor as part of a combination ,'}, {'start':(10, 21), 'end':(10, 27), 'text':'as shown for BRAF mutant cancers .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 14), 'text':'One of the most important biomarkers for GBM is the methylation status of MGMT ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 15), 'end':(11, 24), 'text':'which predicts sensitivity to temozolomide , , an alkylating agent'}, {'start':(11, 25), 'end':(11, 35), 'text':'that is the current standard of care for GBM patients .'}]}]}]}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(12, 0), 'end':(12, 19), 'text':'Integrative analysis of mutation , DNA methylation and clinical ( treatment ) data , albeit with small sample numbers ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 20), 'end':(12, 26), 'text':'suggests a series of inter related events'}, {'start':(12, 27), 'end':(12, 34), 'text':'that may impact clinical response and outcome .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 20), 'text':'Newly diagnosed glioblastomas with MGMT methylation respond well to treatment with alkylating agents , in part as a consequence of unrepaired'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 21), 'end':(13, 23), 'text':'alkylated guanine residues'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 24), 'end':(13, 30), 'text':'initiating cycles of futile mismatch repair ,'}, {'start':(13, 31), 'end':(13, 37), 'text':'which can lead to cell death -.'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 14), 'text':'Therefore , treatment of MGMT deficient GBMs with alkylating therapy introduces a strong selective pressure'}, {'start':(14, 15), 'end':(14, 20), 'text':'to lose mismatch repair function .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 6), 'text':'That conclusion is consistent with our observation'}, {'start':(15, 7), 'end':(15, 18), 'text':'that the mismatch repair genes themselves are mutated with characteristic C :'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 19), 'end':(15, 19), 'text':'G'}, {'start':(15, 20), 'end':(15, 23), 'text':'-- > A :'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 24), 'end':(15, 29), 'text':'T transitions at non CpG sites'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 30), 'end':(15, 32), 'text':'resulting from unrepaired'}, {'start':(15, 33), 'end':(15, 36), 'text':'alkylated guanine residues .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 29), 'text':'Thus , initial methylation of MGMT , in conjunction with treatment , may lead to both a shift in mutation spectrum affecting mutations at mismatch repair genes and selective pressure'}, {'start':(16, 30), 'end':(16, 35), 'text':'to lose mismatch repair function .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 0), 'end':(17, 8), 'text':'In other words , our finding raises the possibility'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 9), 'end':(17, 10), 'text':'that patients'}, {'start':(17, 11), 'end':(17, 35), 'text':'who initially respond to the frontline therapy in use today may evolve not only treatment resistance , but also an MMR defective hypermutator phenotype .'}]}]}, {'label':'condition', 'direction':'RightToLeft', 'children':[{'start':(18, 0), 'end':(18, 11), 'text':'If such a mechanism indeed underlies emergence of MMR defective resistance ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(18, 12), 'end':(18, 14), 'text':'one may speculate'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(18, 15), 'end':(18, 17), 'text':'that selective strategies'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 18), 'end':(18, 26), 'text':'targeting mismatch-repair deficiency would represent a rational upfront combination'}, {'start':(18, 27), 'end':(18, 36), 'text':'that may prevent or minimize emergence of such resistance .'}]}]}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 0), 'end':(19, 14), 'text':'Validation of this hypothesis will have immediate clinical impact and implication for therapeutic design .'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(20, 0), 'end':(20, 4), 'text':'For one , it suggests'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 5), 'end':(20, 14), 'text':'that treatment mediated mutator phenotype may lead to pathway mutations'}, {'start':(20, 15), 'end':(20, 19), 'text':'that confer resistance to new'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 20), 'end':(20, 21), 'text':'targeted therapies'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 22), 'end':(20, 25), 'text':'thereby raising the concern'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 26), 'end':(20, 35), 'text':'that combined or serial treatment with alkylating agents and pathway'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 36), 'end':(20, 42), 'text':'targeted therapies may substantially increase the probability'}, {'start':(20, 43), 'end':(20, 50), 'text':'of developing resistance to such targeted drugs .'}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 6), 'text':'In conclusion , the power of TCGA'}, {'start':(21, 7), 'end':(21, 12), 'text':'to produce unprecedented multi-dimensional data sets'}]}, {'start':(21, 13), 'end':(21, 33), 'text':'employing statistically robust numbers of samples sets the stage for a new era in the discovery of new cancer interventions .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 0), 'end':(22, 2), 'text':'The integrative analyses'}, {'start':(22, 3), 'end':(22, 26), 'text':'leading to formulation of an unanticipated hypothesis on a potential mechanism of resistance highlights precisely the value and power of such project design ,'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(22, 27), 'end':(22, 27), 'text':'demonstrating'}, {'start':(22, 28), 'end':(22, 45), 'text':'how unbiased and systematic cancer genome analyses of large sample cohorts can lead to paradigm shifting discoveries .'}]}]}]}]}]}
239	240	{'start':(0, 0), 'end':(0, 0), 'text':'Figures'}
236	237	{'start':(0, 0), 'end':(0, 1), 'text':'Supplementary Material'}
237	239	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'1'}, {'start':(1, 0), 'end':(1, 17), 'text':'Full Methods and any associated references are available in the online version of the manuscript at www.nature.com/nature .'}]}
136	148	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 1), 'text':'Method Summary'}, {'start':(1, 0), 'end':(1, 25), 'text':'Biospecimens were screened from retrospective banks of Tissue Source Sites under appropriate IRB approvals for newly diagnosed GBM with minimal 80 % tumor cell percentage .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 2), 'text':'RNA and DNA'}, {'start':(2, 3), 'end':(2, 14), 'text':'extracted from qualified specimens were distributed to TCGA centers for analysis .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 16), 'text':'Whole genome amplified genomic DNA samples from tumors and normals were sequenced by the Sanger method .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 3), 'text':'Mutations were called ,'}, {'label':'temporal', 'direction':'None', 'children':[{'start':(4, 4), 'end':(4, 10), 'text':'verified using a second genotyping platform ,'}, {'label':'temporal', 'direction':'LeftToRight', 'children':[{'start':(4, 11), 'end':(4, 18), 'text':'and systematically analyzed to identify significantly mutated genes'}, {'start':(4, 19), 'end':(4, 36), 'text':'after correcting for the background mutation rate for nucleotide type and the sequence coverage of each gene .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 5), 'text':'DNA copy number analyses were performed'}, {'start':(5, 6), 'end':(5, 22), 'text':'using the Agilent 244K , Affymetrix SNP6 .0 , and Illumina 550K DNA copy number platforms .'}]}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 8), 'text':'Sample specific and recurrent copy number changes were identified'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 9), 'end':(6, 11), 'text':'using various algorithms'}, {'start':(6, 12), 'end':(6, 19), 'text':'( GISTIC , GTS , RAE ) .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 6), 'text':'mRNA and miRNA expression profiles were generated'}, {'start':(7, 7), 'end':(7, 25), 'text':'using Affymetrix U133A , Affymetrix Exon 1.0 ST , custom Agilent 244K , and Agilent miRNA array platforms .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 19), 'text':'mRNA expression profiles were integrated into a single estimate of relative gene expression for each gene in each sample .'}, {'start':(9, 0), 'end':(9, 11), 'text':'Methylation at CpG dinucelotides was measured using the Illumina GoldenGate assay .'}]}]}]}]}, {'start':(10, 0), 'end':(10, 31), 'text':'All data for DNA sequence alterations , copy number , mRNA expression , miRNA expression , and CpG methylation were deposited in standard common formats in the TCGA DCC at http://cancergenome.nih.gov/dataportal/ .'}]}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 1), 'text':'All archives'}, {'start':(11, 2), 'end':(11, 6), 'text':'submitted to DCC were validated'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(11, 7), 'end':(11, 12), 'text':'to ensure a common document structure'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 13), 'end':(11, 17), 'text':'and to ensure proper use'}, {'start':(11, 18), 'end':(11, 21), 'text':'of identifying information .'}]}]}]}]}
